Skip to main content
NCBI home page
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2016 Apr 13;16(4):633–639. doi: 10.3233/CBM-160605

PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma

Zihua Li 1,*, Tu Lv 1, Youyu Liu 1, Xuesong Huang 1, Zhongpeng Qiu 1, Jianjun Li 1
PMCID: PMC13016521  PMID: 27002766

Abstract

OBJECTIVE:

To evaluate the expression of PARP1 in chordoma and analyzed its association with clinical factors and patients' prognosis.

METHODS:

The expression of Poly (ADP-ribose) polymerase 1 (PARP1) in chordoma specimens from 74 chordoma patients (50 primary and 24 recurrent tumors of 50 patients)and 20 distant normal tissue specimens was measured by immunohistochemical staining. The association of PARP1with the clinical factors and patients' prognosis was also analyzed.

RESULTS:

Of all the chordoma samples, 78% showed high expression of PARP1, whereas, only 10% of distant normal tissues expressed a high level of PARP1 (p< 0.01). Chi-square analysis revealed that high expression of PARP1 was significantly correlated with tumor recurrence (p< 0.01) and invasion into surrounding muscle (p< 0.01), while the data did not indicate any association with patients' gender, age, tumor location and size (p> 0.05). Kaplan-Meier survival curve and log-rank test showed that continuous disease free survival time (CDFS) was significantly shorter in the PARP1-positive group than in the PARP1-negative group (P= 0.019).

CONCLUSION:

High expression of PARP1 is significantly associated with chordoma invasion and recurrence. PARP1 may become a potential biomarker for chordoma in predicting its recurrence and patients' prognosis.

Keywords: Chordoma, recurrence, PARP1, prognosis

Full Text

The Full Text of this article is available as a PDF (962.8 KB).

References

  • [1]. Matsumoto T., Imagama S., Ito Z., Imai R., Kamada T., Shimoyama Y., Matsuyama Y. and Ishiguro N., Total spondylectomy following carbon ion radiotherapy to treat chordoma of the mobile spine, Bone Joint J 95-B(10) (2013), 1392-1395. [DOI] [PubMed] [Google Scholar]
  • [2]. MacMaster M.S., Goldstein A.M., Bromley C.M., Ishibe N. and Parry D.M., Chordoma: incidence and survival patterns in the United States, 1973-1995, Cancer Causes Control 12(1) (2001), 1-11. [DOI] [PubMed] [Google Scholar]
  • [3]. Bergh P., Kingblom L.G. Gunterberg B., Remotti F., Ryd W. and Meis-Kindblom J.M., Prognostic factors in chordoma of the sacrum and mobile spine. A study of 39 patients, Cancer 88(9) (2000), 2122-2134. [DOI] [PubMed] [Google Scholar]
  • [4]. Moojen W.A., Vleggeert-Lankamp C.L., Krol A.D. and Dijkstra S.P., Long-term results: adjuvant radiotherapy in en bloc resection of sacrococcygeal chordoma is advisable, Spine (Phila Pa 1976) 36(10) (2011), E656-61. [DOI] [PubMed] [Google Scholar]
  • [5]. McPherson C.M., Suki D., McCutcheon I.E., Gokaslan Z.L., Rhines L.D. and Mendel E., Metastatic disease from spinal chordoma: a 10-year experience, J Neurosurg Spine 5(4) (2006), 277-280. [DOI] [PubMed] [Google Scholar]
  • [6]. Ruggieri P., Angelini A., Ussia G., Montalti M. and Mercuri M., Surgical margins and local control in resection of sacral chordomas, Clin Orthop Relat Res 468(11) (2010), 2939-2947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7]. Sciubba D.M., Cheng J.J., Petteys R.J., Weber K.L., Frassica D.A. and Gokaslan Z.L., Chordoma of the sacrum and vertebral bodies, J Am Acad Orthop Surg 17(11) (2009), 708-717. [DOI] [PubMed] [Google Scholar]
  • [8]. Hanna S.A., Aston W.J., Briggs T.W., Cannon S.R. and Saifuddin A., Sacral chordoma: can local recurrence after sacrectomy be predicted? Clin Orthop Relat Res 466(9) (2008), 2217-2223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9]. Zaremba T. and Curtin N.J., PARP inhibitor development for systemic cancer targeting, Anticancer Agents Med Chem 7(5) (2007), 515-523. [DOI] [PubMed] [Google Scholar]
  • [10]. Rouleau M., Patel A., Hendzel M.J., Kaufmann S.H. and Poirier G.G., PARP inhibition: PARP1 and beyond, Nat Rev Cancer 10(4) (2010), 293-301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11]. Deshmukh D. and Qiu Y., Role of PARP-1 in prostate cancer, Am J Clin Exp Urol 3(1) (2015), 1-12. [PMC free article] [PubMed] [Google Scholar]
  • [12]. Scheipl S., Lohberger B., Rinner B., Froehlich E.V., Beham A., Quehenberger F., Lazáry A., Pal Varga P., Haybaeck J., Leithner A. and Liegl B., Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: an immunohistochemical and functional analysis, J Orthop Res 31(12) (2013), 1999-2005. [DOI] [PubMed] [Google Scholar]
  • [13]. Yang H., Zhu L., Ebraheim N.A., Liu X., Castillo S., Tang T., Liu J. and Cui H., Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization, Spine J 9(12) (2009), 972-980. [DOI] [PubMed] [Google Scholar]
  • [14]. Chen K., Mo J., Zhou M., Wang G., Wu G., Chen H., Zhang K. and Yang H., Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis, Med Oncol 31(4) (2014), 886. [DOI] [PubMed] [Google Scholar]
  • [15]. Chen K.W., Yang H.L., Lu J., Liu J.Y. and Chen X.Q., Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients, Spinal Cord 48(2) (2010), 166-171. [DOI] [PubMed] [Google Scholar]
  • [16]. Chen K.W., Yang H.L., Lu J., Wang G.L., Ji Y.M., Wu G.Z., Zhu L.F., Liu J.Y., Chen X.Q. and Gu Y.P., Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma, J Neurooncol 101(3) (2011), 357-363. [DOI] [PubMed] [Google Scholar]
  • [17]. Rinner B., Froehlich E.V., Buerger K., Knausz H., Lohberger B., Scheipl S., Fischer C., Leithner A., Guelly C., Trajanoski S., Szuhai K. and Liegl B., Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1, Int J Oncol 40(2) (2012), 443-451. [DOI] [PubMed] [Google Scholar]
  • [18]. Na Z., Peng B., Ng S., Pan S., Lee J.S., Shen H.M. and Yao S.Q., A small-molecule protein-protein interaction inhibitor of PARP1 that targets its BRCT domain, Angew Chem Int Ed Engl 54(8) (2015), 2515-2519. [DOI] [PubMed] [Google Scholar]
  • [19]. Xu Z., Zhang L., Zhang W., Meng D., Zhang H., Jian Y., Xu X., Van Meter M., Seluanov A., Gorbunova V. and Mao Z., SIRT6 rescues the age related decline in base excision repair in a PARP1-dependent manner, Cell Cycle 14(2) (2015), 269-276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20]. Bao M., Chen Z., Xu Y., Zhao Y., Zha R., Huang S., Liu L., Chen T., Li J., Tu H. and He X., Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma, Liver Int 32(2) (2012), 331-338. [DOI] [PubMed] [Google Scholar]
  • [21]. Veith S. and Mangerich A., RecQ helicases and PARP1 team up in maintaining genome integrity, Ageing Res Rev 23(Pt A) (2015), 12-28. [DOI] [PubMed] [Google Scholar]
  • [22]. Scheil S., Bruderlein S., Liehr T., Starke H., Herms J., Schulte M. and Möller P., Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1, Genes Chromosomes Cancer 32(3) (2001), 203-211. [DOI] [PubMed] [Google Scholar]
  • [23]. Akhavan-Sigari R., Gaab M.R., Rohde V., Abili M. and Ostertag H., Expression of PDGFR-alpha, EGFR and c-MET in spinal chordoma: a series of 52 patients, Anticancer Res 34(2) (2014), 623-630. [PubMed] [Google Scholar]
  • [24]. Sajish M. and Schimmel P., A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol, Nature 519(7543) (2015), 370-373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25]. Green A.R., Caracappa D., Benhasouna A.A., Alshareeda A., Nolan C.C., Macmillan R.D., Madhusudan S., Ellis I.O. and Rakha E.A., Biological and clinical significance of PARP1 protein expression in breast cancer, Breast Cancer Res Treat 149(2) (2015), 353-362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26]. Sabbatino F., Fusciello C., Somma D., Pacelli R., Poudel R., Pepin D., Leonardi A., Carlomagno C., Della Vittoria Scarpati G., Ferrone S. and Pepe S., Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation, Cytometry A 85(11) (2014), 953-961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27]. Dziaman T., Ludwiczak H., Ciesla J.M., Banaszkiewicz Z., Winczura A., Chmielarczyk M., Wisniewska E., Marszalek A., Tudek B. and Olinski R., PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1, PLoS One 9(12) (2014), e115558. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES